PhytoMedical Technologies, Inc. is currently focusing its efforts on the anti-cancer compound for glioblastoma, D11B, to which the company has an exclusive license, pursuant to a license agreement with the Trustees of Dartmouth College. The company’s Board of Directors is evaluating whether it is in the best interests to continue to expend its capital resources on the development of the D11B compound or to explore other viable business ventures and opportunities. The company was founded in 2001 and is based in Princeton, New Jersey.
A few weeks after PhytoMedical Technologies, Inc. (OTC:PYTO) announced their plans to start a new era in their business, yesterday the share price finally surged up. That surge resulted from a costly stock promotion and suspiciously resembles the well-know pumping and dumping.read more
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
A few weeks after PhytoMedical Technologies, Inc. (OTC:PYTO) announced their plans to start a new era in their business, yesterday the share price finally surged up. That surge resulted from a costly stock promotion and suspiciously resembles the well-know pumping and dumping.read more
